Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV.
With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
Location: United States, California, Emeryville
Employees: 51-200
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Frazier Li... | frazierls.... |
Mentions in press and media 10
| Date | Title | Description | Source |
| 05.03.2024 | Gritstone bio Reports Fourth Quarter and Full Year 2023 Fina... | - | globenewsw... |
| 09.08.2023 | Gritstone bio Reports Second Quarter 2023 Financial Results ... | -- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cance... | einpresswi... |
| 11.05.2023 | Gritstone bio Reports First Quarter 2023 Financial Results a... | /EIN News/ -- -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (pers... | einpresswi... |
| 13.01.2022 | Gritstone Announces First Patient Enrolled for Phase 2/3 Tri... | -- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial ... | marketscre... |
| 25.10.2021 | Gritstone bio : Announces Presentations during Five Upcoming... | EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical... | marketscre... |
| 16.09.2021 | Gritstone bio : Announces Private Placement Financing of $55... | EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinica... | marketscre... |
| 08.09.2021 | Here’s how Seqera Labs helps identify COVID-19 variants; rai... | Barcelona-based Seqera Labs has announced that it raised $5.5M(€4.6M) in a seed funding round co-led... | siliconcan... |
| 07.09.2021 | Gritstone bio : Announces Presentations at Two Investor Conf... | EMERYVILLE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinica... | marketscre... |
| 17.08.2021 | Covid-19 roundup: CEPI injects $20.6M into Gritstone's pu... | As the Delta variant drives a global surge in Covid-19 cases, the Coalition for Epidemic Pre... | endpts.com... |
| - | COVID-19 vaccines revolutionized RNA — now everyone else wan... | Employees in special suits test procedures for manufacturing the messenger-RNA COVID-19 vaccine from... | businessin... |